Negara: Amerika Serikat
Bahasa: Inggris
Sumber: NLM (National Library of Medicine)
SPIRONOLACTONE (UNII: 27O7W4T232) (SPIRONOLACTONE - UNII:27O7W4T232)
NCS HealthCare of KY, Inc dba Vangard Labs
SPIRONOLACTONE
SPIRONOLACTONE 25 mg
ORAL
PRESCRIPTION DRUG
Spironolactone tablets are indicated in the management of: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. For nephrotic patient
Spironolactone Tablets, USP are available containing 25 mg, 50 mg or 100 mg of spironolactone, USP. The 25 mg tablet is a white, film-coated, round, unscored tablet debossed with M over 146 on one side of the tablet and blank on the other side. They are available as follows: NDC 0615-1535-39 blisterpacks of 30 tablets NDC 0615-1535-31 blisterpacks of 31 tablets NDC 0615-1535-05 blisterpacks of 15 tablets The 50 mg tablet is a white, film-coated, round tablet debossed with M over 243 on one side of the tablet and scored on the other side. They are available as follows: NDC 0615-5592-39 blisterpacks of 30 tablets The 100 mg tablet is a white, film-coated, round tablet debossed with M over 437 on one side of the tablet and scored on the other side. They are available as follows: NDC 0615-6591-39 blisterpacks of 30 tablets Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Mylan Pharmaceuticals Inc. Morgantown, WV 26505 REVISED APRIL 2009 SP:R19
Abbreviated New Drug Application
SPIRONOLACTONE- SPIRONOLACTONE TABLET, FILM COATED NCS HEALTHCARE OF KY, INC DBA VANGARD LABS ---------- SPIRONOLACTONE WARNING Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS). Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. DESCRIPTION Spironolactone oral tablets contain 25 mg, 50 mg or 100 mg of the aldosterone antagonist spironolactone, 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate, which has the following structural formula, molecular formula, and molecular weight: C H O S M.W.=416.59 Spironolactone, USP is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Each tablet for oral administration contains 25 mg, 50 mg or 100 mg of spironolactone, USP and the following inactive ingredients: calcium sulfate dihydrate, colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, peppermint flavor, polydextrose, polyethethylene glycol, povidone, pregelatinized starch, sodium lauryl sulfate, titanium dioxide and triacetin. ACTIONS/CLINICAL PHARMACOLOGY MECHANISM OF ACTION Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally 24 32 4 in the renal tubule. ALDOSTERONE ANTAGONIST ACTIVITY Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Edematous states in which secondary aldosteronism is usually involved include congestive heart fa Baca dokumen lengkapnya